HIM
BBIO icon

Hillhouse Investment Management’s BridgeBio Pharma BBIO Stock Holding History

Hillhouse Investment Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$54.9M Buy
+2,035,790
New +$55.5M 1.75% 13

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hillhouse Investment Management's BBIO Position: Q2 2019 in Review

Hillhouse Investment Management opened a new position in BridgeBio Pharma (BBIO) in Q2 2019: 2,035,790 shares worth $54.9M. The stake represents 1.75% of the portfolio and ranks #13 among its holdings.

61 funds tracked by Wall St. Rank hold BBIO as of Q2 2019.

  • Hillhouse Investment Management held 2,035,790 shares of BridgeBio Pharma worth $54.9M as of Q2 2019.
  • BridgeBio Pharma was a new Hillhouse Investment Management position in Q2 2019.
  • BridgeBio Pharma made up 1.75% of Hillhouse Investment Management's portfolio in Q2 2019, its #13 holding.
  • 61 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2019.

Based on Hillhouse Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.